Document is current
Any future updates will be listed below
-
Authors
Yang, Yang https://orcid.org/0000-0002-5560-2936
Badura, Michelle L.
O’Leary, Patrick C.
Delavan, Henry M.
Robinson, Troy M.
Egusa, Emily A.
Zhong, Xiaoming
Swinderman, Jason T.
Li, Haolong https://orcid.org/0000-0002-8628-9698
Zhang, Meng https://orcid.org/0000-0003-1042-6294
Kim, Minkyu
Ashworth, Alan https://orcid.org/0000-0003-1446-7878
Feng, Felix Y. https://orcid.org/0000-0002-0963-7687
Chou, Jonathan https://orcid.org/0000-0003-1258-0391
Yang, Lixing https://orcid.org/0000-0001-9618-2117
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA269977)
Prostate Cancer Foundation
U.S. Department of Defense
- License Information
-
More Information
Article History
Received: 24 January 2023
Accepted: 4 October 2024
First Online: 18 November 2024
Competing interests
: A.A. reports personal fees from Tango Therapeutics, Azkarra Therapeutics, Ovibio, Kytarro, CytomX, Cambridge Science Corporation, Genentech, Gladiator, Circle, Bluestar, Earli, Ambagon, Trial Library, Phoenix Molecular Designs, GSK, Prolynx; grants from SPARC and AstraZeneca outside the submitted work. In addition, he holds patents on the use of PARP inhibitors held jointly with AstraZeneca from which he has benefited financially (and may do so in the future). F.Y.F. reports personal fees from Bluestar Genomics, Astellas, Foundation Medicine, Exact Sciences, Tempus, POINT Biopharma, Janssen, Bayer, Myovant, Roivant, SerImmune, Bristol Myers Squibb and Novartis, and personal fees from POINT Biopharma outside the submitted work and other support from Artera. J.C. reports consulting fees from Exai Bio outside the submitted work. The other authors declare no competing interests.
